Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Incannex HealthcareIXHL -5.45%32 EV-to-EBITDA is 0.81 as of Jul. 26, 2026. GuruFocus rates IXHL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 742 Drug Manufacturers companies, Incannex Healthcare ranks better than 96.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Incannex Healthcare's enterprise value is $-39.04 Mil.
Incannex Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-48.16 Mil. Therefore, Incannex Healthcare's EV-to-EBITDA for today is 0.81.
The historical rank and industry rank for Incannex Healthcare's EV-to-EBITDA or its related term are showing as below:
IXHL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.08 Med: -1.01 Max: 0.91
Current: 0.81
During the past 13 years, the highest EV-to-EBITDA of Incannex Healthcare was 0.91. The lowest was -4.08. And the median was -1.01.
IXHL's EV-to-EBITDA is ranked better than 96.63% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs IXHL: 0.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Incannex Healthcare's PE Ratio (TTM) for today is calculated as:
Incannex Healthcare's share price for today is $2.95.
Incannex Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.428.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Incannex Healthcare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incannex Healthcare EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Incannex Healthcare's EV-to-EBITDA falls into.
Incannex Healthcare's current Enterprise Value is $-39.04 Mil.
Incannex Healthcare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incannex Healthcare (IXHL) has a EV-to-EBITDA of 0.81 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Incannex Healthcare. According to the industry distribution chart, Incannex Healthcare ranks #25 out of 742 companies in the Drug Manufacturers industry, placing it in the top 3.4%.
Is Incannex Healthcare's EV-to-EBITDA too high?
Incannex Healthcare's current EV-to-EBITDA is 0.81. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Incannex Healthcare's value of 0.81 is 93.8% below this industry median. Based on the distribution chart, Incannex Healthcare ranks #25 out of 742 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Incannex Healthcare has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Incannex Healthcare's EV-to-EBITDA compare to BTAI and SCYX?
According to the Drug Manufacturers industry distribution chart, Incannex Healthcare ranks #25 out of 742 companies for EV-to-EBITDA. This places Incannex Healthcare in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.98. Incannex Healthcare's value of 0.81 is 93.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incannex Healthcare's current EV-to-EBITDA of 0.81 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Incannex Healthcare. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incannex Healthcare's current EV-to-EBITDA is 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incannex Healthcare stock overvalued right now?
Incannex Healthcare (IXHL) has a current EV-to-EBITDA of 0.81. The current EV-to-EBITDA is 0.81 and 93.8% below the Drug Manufacturers industry median of 12.98. Incannex Healthcare's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Incannex Healthcare (IXHL), the current EV-to-EBITDA is 0.81 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
32GF Score
Get the complete analysis for IXHL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IXHL has been successfully added to your 
